BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 31, 2024
See today's BioWorld Asia
Home
» China’s NMPA accepts Hutchmed’s sovleplenib NDA for primary immune thrombocytopenia
To read the full story,
subscribe
or
sign in
.
China’s NMPA accepts Hutchmed’s sovleplenib NDA for primary immune thrombocytopenia
Jan. 16, 2024
By
Tamra Sami
No Comments
China’s National Medical Products Administration (NMPA) has accepted for review Hutchmed’s NDA for sovleplenib (HMPL-523) for treatment of primary immune thrombocytopenia.
BioWorld Asia
Regulatory
Hematologic
Asia-Pacific
China
NDA
NMPA
